Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Immunohistochemical markers for intracranial ependymoma recurrence - An analysis of 88 cases
Autore:
Korshunov, A; Golanov, A; Timirgaz, V;
Indirizzi:
NN Burdenko Neurosurg Res Inst, Dept Neuropathol, Moscow, Russia NN Burdenko Neurosurg Res Inst Moscow Russia europathol, Moscow, Russia NN Burdenko Neurosurg Res Inst, Dept Neurooncol Surg, Moscow, Russia NN Burdenko Neurosurg Res Inst Moscow Russia oncol Surg, Moscow, Russia
Titolo Testata:
JOURNAL OF THE NEUROLOGICAL SCIENCES
fascicolo: 1, volume: 177, anno: 2000,
pagine: 72 - 82
SICI:
0022-510X(20000801)177:1<72:IMFIER>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
ENDOTHELIAL GROWTH-FACTOR; POSTERIOR-FOSSA EPENDYMOMAS; MOLECULAR-GENETIC ANALYSIS; HUMAN ASTROCYTIC GLIOMAS; HUMAN BRAIN-TUMORS; PROGNOSTIC FACTORS; PEDIATRIC EPENDYMOMAS; P27/KIP1 EXPRESSION; NERVOUS-SYSTEM; SURVIVAL;
Keywords:
apoptosis; ependymoma; immunohistochemistry; p53 protein; prognosis; tenascin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
67
Recensione:
Indirizzi per estratti:
Indirizzo: Korshunov, A NN Burdenko Neurosurg Res Inst, Dept Neuropathol, Moscow, Russia NN Burdenko Neurosurg Res Inst Moscow Russia oscow, Russia
Citazione:
A. Korshunov et al., "Immunohistochemical markers for intracranial ependymoma recurrence - An analysis of 88 cases", J NEUR SCI, 177(1), 2000, pp. 72-82

Abstract

Intracranial ependymomas are the third most common primary brain tumor in children. Although clinical and histological criteria for ependymoma prognosis are recognized, studies have reported contradictory results. Prognosticsignificance based on immunohistochemistry of ependymomas has been reported in a few studies. Eighty-eight patients with intracranial ependymomas were examined retrospectively for immunoexpression of various tumor-associatedantigens and apoptosis. The results demonstrated significant preponderanceof expression of the tenascin, vascular endothelial growth factor protein (VEGF), epidermal growth factor (EGFR), and p53 protein in high-grade tumors. Also high-grade ependymomas revealed more prominent labeling indices (LI) for proliferative marker Ki-S1 and lower LI for cyclin-dependent kinase inhibitor p27/Kip1. For low-grade ependymomas the progression free survival time (PFS) was found to be significantly shorter for Ki-S1 LI greater than or equal to 5%, and for tenascin, VEGF, and EGFR positivity. For high-gradeependymomas PFS was found to be significantly reduced for age < 16 years, subtotal tumor removal, p27 LI < 20%, p53 positivity, and for apoptotic index (AI) < 1%. The classification regression tree analysis exhibited four groups of ependymomas; (1) low-grade tenascin negative (32 cases, recurrence rate = 0), (2) high-grade with AI greater than or equal to 1% (21 cases, recurrence rate = 57%), (3) low-grade tenascin-positive (10 cases, recurrencerate = 89%), and (4) high-grade with AI < 1% (25 cases, recurrence rate = 100%). So, the immunohistochemical variables were found to be strongest predictors of ependymoma recurrence and they seem to be useful for assessing individual tumor prognosis in routinely processed biopsy specimen. (C) 2000 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 14:40:40